Infliximab is a chimeric monoclonal antibody that neutralizes tumor necrosis factor-alpha (TNF-α), a pro-inflammatory cytokine central to neuroinflammation in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions. It is FDA-approved for autoimmune diseases including rheumatoid arthritis, Crohn's disease, ulcerative colitis, and ankylosing spondylitis, and is being investigated for neuroprotection in degenerative brain diseases.
TNF-alpha is a key mediator of chronic neuroinflammation:
-
Pro-inflammatory Signaling: TNF-α activates NF-κB and MAPK pathways in microglia and astrocytes, leading to production of more cytokines and chemokines. This creates a self-perpetuating inflammatory loop that drives progressive neuronal dysfunction.
-
Excitotoxicity: TNF-α enhances glutamate-induced neuronal toxicity by increasing AMPA receptor trafficking to the synaptic membrane, leading to calcium dysregulation and excitotoxic cell death.
-
Blood-Brain Barrier Disruption: TNF-α increases BBB permeability by downregulating tight junction proteins (claudin-5, occludin), allowing peripheral immune cells to enter the CNS and exacerbate inflammation.
-
Synaptic Pruning: Elevated TNF-α promotes excessive synaptic elimination by microglia through complement-mediated pathways, contributing to synaptic loss in AD and PD.
-
Mitochondrial Dysfunction: TNF-α signaling impairs mitochondrial function by inhibiting complex I and increasing reactive oxygen species (ROS) production.
Infliximab is a chimeric IgG1 monoclonal antibody that:
- Binds to both soluble and membrane-bound TNF-α with high affinity (KD ~ 10^-11 M)
- Prevents TNF-α from binding to its receptors (TNFR1/p55, TNFR2/p75)
- May induce apoptosis of TNF-α-expressing cells through antibody-dependent cellular cytotoxicity
- Does not bind to other TNF family members (lymphotoxin-α, TRAIL)
- Phase II trial sponsored by University of California, Los Angeles
- Objective: Evaluate infliximab safety and CSF biomarkers in mild cognitive impairment and AD
- Status: Completed (results published 2023)
- Key findings: Treatment was safe; trend toward reduction in CSF inflammatory markers
- Preclinical evidence: TNF-α levels are elevated in PD brains (substantia nigra) and CSF
- Case reports: Patients with comorbid autoimmune disease showed PD symptom improvement on TNF inhibitors
- Observational studies: Reduced PD incidence in patients on chronic TNF therapy for autoimmune conditions
- No large Phase II/III trials completed as of 2026
- Rationale: Neuroinflammation is a key contributor to ALS progression
- Evidence: Elevated TNF-α in ALS patient CSF and spinal cord
- Clinical trials: No completed trials as of 2026
- Paradoxical finding: TNF inhibitors can trigger demyelinating disease
- Lesson: Timing and patient selection are critical for anti-TNF therapy in CNS diseases
¶ Dosage and Administration
In autoimmune diseases:
- Induction: 3-5 mg/kg IV at weeks 0, 2, 6
- Maintenance: Every 8 weeks thereafter
For neurodegeneration trials, similar dosing has been used:
- 5 mg/kg IV infusion over 2 hours
- Pre-medication with antihistamine and acetaminophen recommended
- Monitoring required for infusion reactions
Common (>10%):
- Infusion reactions (headache, flushing, dyspnea)
- Headache
- Upper respiratory infections
- Nausea
Serious:
- Serious infections (reactivation of TB, bacterial, fungal)
- Heart failure exacerbation
- Demyelinating disease
- Liver injury (elevated transaminases)
- Increased risk of certain malignancies (lymphoma, non-melanoma skin cancer)
- Psoriasis or psoriasiform eruptions
| Drug |
Target |
Route |
Neurodegeneration Trials |
Notes |
| Infliximab |
TNF-α |
IV |
AD, PD (Phase II) |
Chimeric antibody |
| Etanercept |
TNF-α |
SC |
PD (mixed results) |
Fusion protein |
| Adalimumab |
TNF-α |
SC |
PD |
Fully human antibody |
| Tocilizumab |
IL-6R |
IV/SC |
AD, PD (Phase II) |
Approved for RA |
| Anakinra |
IL-1β |
SC |
AD |
Short half-life |
| Secukinumab |
IL-17A |
SC |
None |
Different pathway |
- Select patients with elevated peripheral inflammatory markers (CRP, IL-6)
- Use CSF TNF-α or sTREM2 levels as enrichment biomarkers
- Target patients with evidence of systemic inflammation
- Combine with disease-modifying therapies targeting protein aggregation
- Pair with anti-amyloid or anti-tau immunotherapies
- Use with antioxidants or mitochondrial protectants
- Earlier intervention in prodromal or mild cognitive impairment stages
- Consider preventive therapy in high-risk populations
- Avoid in patients with established advanced neurodegeneration
- Investigate intrathecal or convection-enhanced delivery for higher CNS penetration
- Develop TNF-neutralizing fragments with better brain access
The study of Infliximab For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.